Targets › GABRB3
36 programs from 34 companies in 65 trials: 32 Phase 4, 13 Phase 3, 12 Phase 2, 8 Phase 1; Other, Psychiatry, Neurology; next expected readout Nov 2026.
Beta subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain. GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s). (UniProt, P28472)
Open in Phaseline: the race on GABRB3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rush University Medical Center | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Minor Surgical Procedures With Monitored Anesthesia Care | Nov 2026 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Propofol GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Lung Cancer; Hepatocellular Carcinoma; Ovarian Cancer | Nov 2026 |
| University of Sao Paulo | Eszopiclone GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Insomnia | Dec 2026 |
| Medical University of South Carolina | Remimazolam besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Burn Scar | Jan 2027 |
| Medical University of South Carolina | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Anesthesia Induction | Apr 2027 |
| Seoul National University Hospital | Remimazolam Besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Remimazolam; Aortic Aneurysm, Thoracoabdominal | Apr 2027 |
| SK Life Science | Cenobamate (YKP3089) GABA-A receptor; anion channel positive allosteric modulator; Sodium channel alpha subunit inhibitor | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Focal Onset Seizure; Partial Epilepsy | May 2027 |
| Clinical Hospital Centre Zagreb | Remimazolam besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Colonic Polyp | Nov 2027 |
| Laureate Institute for Brain Research, Inc. | Lorazepam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Depression, Anxiety | Dec 2027 |
| David Lyubashevsky | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Transcatheter Aortic Valve Replacement (TAVR) | Apr 2028 |
| VA Office of Research and Development | Lorazepam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Stress Disorders, Post-Traumatic | Jun 2029 |
| Haisco Pharmaceutical Group | Cipepofol (HSK3486) GABA-A receptor; anion channel agonist | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Anesthesia; Myocardial Injury | – |
| University of Oklahoma | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Laceration of Skin | – |
| Universidade Federal de Goias | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Child Behavior | – |
| Beijing Shijitan Hospital, Capital Medical University | Remimazolam Besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Effect of Drug | – |
| Xi'an Aerospace General Hospital | Remimazolam besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Cholelithiasis | – |
| University of California, Los Angeles | CBD 20 mg GABA-A receptor; anion channel positive allosteric modulator | HTR1A, GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, SLC1A2, SLC1A3 | Phase 3 | Spinocerebellar Ataxias; Non-healing Wound; Sleep Apnea, Obstructive; Cervical Spinal Cord Injury … | Dec 2026 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Laceration of Skin | Dec 2026 |
| University of Texas Southwestern Medical Center | Propofol GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Anesthesia | Jan 2027 |
| Ono Pharmaceutical | Cenobamate GABA-A receptor; anion channel positive allosteric modulator; Sodium channel alpha subunit inhibitor | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Partial Epilepsy; Epilepsies, Partial | Jan 2027 |
| Southeast University, China | Remimazolam besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Remimazolam Besylate | Jan 2027 |
| UCB Biopharma SRL | Alprazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Stereotypical Prolonged Seizures; Ophthalmology; Opioid Abuse; Drug Interactions | Mar 2027 |
| Lipocine | Brexanolone GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Depression, Postpartum; Alzheimer Dementia; PTSD | Aug 2027 |
| University Hospital, Montpellier | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Anesthesia | Oct 2027 |
| Yale University | Eszopiclone GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Sleep Apnea | Jan 2030 |
| Stanford University | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Seizures | – |
| Romanian Society for Enteral and Parenteral Nutrition | Remimazolam Besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Postoperative Cognitive Dysfunction | – |
| Flinders University | Eszopiclone GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | OSA - Obstructive Sleep Apnea | May 2027 |
| Acacia Pharma | Remimazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | Pediatric ALL; Benzodiazepines; Cataract Surgery; Sedation for Diagnostic Gastroscopy … | Oct 2027 |
| University of California, Los Angeles | Eszopiclone GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | Obstructive Sleep Apnea | Aug 2028 |
| M.D. Anderson Cancer Center | Lorazepam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | Delirium | Dec 2028 |
| Insel Gruppe AG, University Hospital Bern | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | Anxiety | – |
| University Hospital, Grenoble | midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 2 | Neurocognitive Disorders | – |
| CAMC Health System | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 1 | Anesthesia | Apr 2027 |
| Qianfoshan Hospital | Remimazolam Besylate GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 1 | Chronic Kidney Diseases | Jun 2027 |
| Makassed General Hospital | Midazolam GABA-A receptor; anion channel positive allosteric modulator | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 1 | Healthy Female Volunteer | – |
Anesthesia (6) Partial Epilepsy (2) Anxiety (2) Laceration of Skin (2) Epilepsies, Partial (1) Neurocognitive Disorders (1) Remimazolam Besylate (1) Obstructive Sleep Apnea (1) Remimazolam (1) Aortic Aneurysm, Thoracoabdominal (1) Depression, Postpartum (1) Alzheimer Dementia (1)
small molecule (35)
University of California, Los Angeles (2) Medical University of South Carolina (2) Ono Pharmaceutical (1) University Hospital, Grenoble (1) Southeast University, China (1) Seoul National University Hospital (1) Lipocine (1) Yale University (1) Kaohsiung Medical University Chung-Ho Memorial Hospital (1) Stanford University (1) Xi'an Aerospace General Hospital (1) Insel Gruppe AG, University Hospital Bern (1) David Lyubashevsky (1) UCB Biopharma SRL (1) Haisco Pharmaceutical Group (1) Clinical Hospital Centre Zagreb (1) University of Texas Southwestern Medical Center (1) University of Oklahoma (1) VA Office of Research and Development (1) Rush University Medical Center (1)
GABRA1 (36) GABRB2 (36) GABRG2 (36) GABRA4 (36) HTR1A (1) SLC1A2 (1) SLC1A3 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.